Fixed-dose combination therapy outperforms prostaglandin alone in reducing diurnal IOP

CORONADO, Calif. — Fixed-dose combination therapy significantly reduced diurnal IOP in patients with ocular hypertension or open-angle glaucoma, according to a poster presented at the American Glaucoma Society meeting.

Robert Fechtner, MD, and fellow authors presented results of a multicenter randomized study that included 88 patients who received brinzolamide 1%/brimonidine 0.2% fixed combination (BBFC) combined with a prostaglandin analogue and 94 patients who received vehicle combined with a prostaglandin analogue.

Drops were administered three times daily for 6 weeks.

Baseline mean diurnal IOP was 22.7 mm Hg in the BBFC group and 22.4 mm Hg in the vehicle group.

IOP was assessed at 8 a.m., 10 a.m., 3 p.m. and 5 p.m. Diurnal IOP and adverse events were also assessed.

The primary outcome measure was mean diurnal IOP at 6 weeks. Secondary measures were IOP at specific time points at 6 weeks and mean change in diurnal IOP from baseline at 6 weeks.

The mean decrease in diurnal IOP from baseline at 6 weeks was 5.7 mm Hg (24.7%) in the BBFC group and 1.9 mm Hg (8.2%) in the vehicle group. The between-group difference was statistically significant (P < .0001).

Diurnal IOP at 6 weeks was 17.1 mm Hg in the BBFC group and 20.5 mm Hg in the vehicle group. The difference was significant (P < .0001).

Mean IOP decreased a mean 7.1 mm Hg (30.9%) in the BBFC group and 2.4 mm Hg (10%) in the vehicle group.

There were 33 adverse events in the BBFC group and 20 in the vehicle group. The most common adverse event in both groups was blurred vision. – by Matt Hasson and Patricia Nale, ELS

Disclosures: Fechtner reports he has received consultant fees from Alcon and Santen. Budenz reports he has received consultant fees from Alcon, Ivantis and Envisia. DuBiner reports he has received speakers bureau fees from Alcon. Khouri reports he has received speakers bureau fees from Alcon and Allergan and research funding from Bausch + Lomb. Myers reports he has received research funding from Aerie Pharmaceuticals, Alcon, Allergan, Glaukos, Inotek and Merck, consultant fees from Alcon, Allergan, Inotek and Sucampo, and lecture fees from Alcon, Allergan and Sucampo.